PNH Drug Market to Reach $1.5B in 2025, Grow at 7.1% CAGR
Image
Las Vegas – September 19, 2026 -- The paroxysmal nocturnal hemoglobinuria (PNH) market across the seven major markets was valued at approximately $1.5 billion in 2025 and is projected to grow at a compound annual growth rate of 7.1% through 2036, according to DelveInsight.
Regeneron's pozelimab-cemdisiran combination leads next wave of PNH therapies
Pozelimab, a fully human anti-C5 monoclonal antibody developed on Regeneron's VelocImmune platform, is expected to generate the highest revenue among emerging PNH therapies in the seven major markets. The drug is being tested in combination with Alnylam's siRNA therapy cemdisiran; Regeneron has said Phase III results in PNH are anticipated in the fourth quarter of 2026 or the first quarter of 2027.